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ABSTRACT 
 
 
 
 
 The main purpose of this study is to simulate the large scale production of 
monoclonal antibody (mAb) by using SuperPro Designer (SPD). Since the first 
discovery of mAb at 1970s, this type of antibody had become the most rapidly growing 
class of pharmaceutical. Problem with mAb production is the high cost and low amount 
of production but high demand for this therapeutic. In order to overcome this problem, 
large scale production had become one of the top priorities for mAb production. Large 
scale simulation study by using SPD can minimize time and cost production by 
eliminate the high cost of trial-and-error steps, as well as to find and simulate the 
optimization process for mAb production. In order to achieve the objective of this 
research, study is conducted in two steps which are simulation on the upstream and 
downstream process. For the upstream process, the stoichiometric equation is 
constructed base on the laboratory data and used to simulate the large volume of 
fermenter. For a downstream process, three flow of downstream process from different 
source a built, simulated and compared to choose the best process for purification of 
mAb. The result shows that the upstream process for 20000 L fermenter produced 
0.00510 kg/Batch of mAb with concentration of 3.8 × 10
-4 
g/L (5.1103 g/Batch). 
Compared to the flow from SPD source and journal (S. Sommerfeld and J. Strube, 
2005), the best downstream process was the flow from Inno Biologics Sdn.Bhd that 
yield 81% of mAb with a concentration of 4.14328 g/Batch. As a conclusion, the 
simulation of large scale production of mAb by using SPD are flow work for 20000 L 
of fermenter as upstream process and Inno Biologics Sdn. Bhd. flow work as 
downstream process. 
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ABSTRAK 
 
 
 
 
 Objektif utama dalam kajian ini adalah untuk simulasi skala besar pengeluaran 
antibodi monoklonal (mAb) dengan menggunakan SuperPro Designer (SPD). Sejak 
pertama kali mAb di temui pada tahun 1970-an, jenis antibodi ini telah berkembang 
pesat untuk industri farmasi. Masalah yang dihadapi dalam pengeluaran mAb adalah 
kos yang tinggi dengan jumlah pengeluaran yang rendah tetapi mempunyai permintaan 
yang tinggi. Untuk mengatasi masalah ini, pengeluaran berskala besar telah menjadi 
salah satu keutamaan untuk pengeluaran mAb. Simulasi skala besar dengan 
menggunakan SPD boleh meminimumkan masa dan kos pengeluaran dengan 
mengurangkan kaedah cuba jaya yang ber kos tinggi, serta mencari proses optimum 
bagi pengeluaran mAb. Untuk mencapai objektif, kajian dilakukan dalam dua langkah 
iaitu simulasi untuk proses huluan dan hiliran. Untuk proses huluan, persamaan 
stoikiometri dibina berdasarkan data makmal dan digunakan untuk simulasi pada 
fermenter yang lebih besar. Untuk proses hiliran, tiga aliran proses hiliran dari sumber 
yang berbeza dibina, disimulasi dan dibandingkan untuk memilih proses yang terbaik 
untuk penulenan mAb. Proses huluan untuk 20000 L fermenter menghasilkan 0.00510 
kg / Batch mAb dengan kepekatan 3,8 × 10 
-4
 g / L (5,1103 g / Batch). Jika sumber SPD 
dan jurnal (S. Sommerfeld dan J. Strube, 2005) dibandingkan dengan Inno Biologics 
Sdn. Bhd, proses hiliran terbaik adalah proses dari Inno Biologics Sdn. Bhd dengan 
81% daripada mAb asal diperolehi dengan kepekatan 4.14328 g / Batch. Kesimpulan 
yang boleh dibuat dari kajian ini adalah simulasi pengeluaran berskala besar mAb 
dengan menggunakan SPD ialah proses fermentasi 20000 L fermenter sebagai proses 
huluan dan proses Inno Biologics Sdn. Bhd sebagai proses hiliran. 
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 CHAPTER 1 
 
 
 
 
INTRODUCTION 
 
 
 
 
1.1 Background of the Study 
 
 
Monoclonal antibody (mAb or moAb) is a class of antibody that produced by a 
single type of immune cell that are all clones of a single parent cell that will recognizes 
a specific antigenic target. The term monoclonal implies antibody produced by a cell 
clone derived from a fusion of one antibody producing cell with one myeloma cell 
capable of growing indefinitely in culture (I. Y. Abdel-Ghany et al., 2009).  Since from 
the first discovery of this technology at 1970s, advances in technology had produce high 
quality of mAb and led the development of excellent therapeutic agents that impact the 
human health. Up until 2009, there are four main type of mAb that is mouse (murine), 
humanized, chimeric and human (E. B. Rodrigues et al., 2009). 
 
 
Since the production of mAb by hybridoma technology, mAb is currently used 
in many applications like the diagnosis and treatment of many diseases or standard 
binding protein for purification of substances (L. Legazpi et al., 2005). One of the 
applications of mAb is treatment for human intoxication like ciguatera seafood 
poisoning. Ciguatoxins are causative toxin for ciguatera is produced by the marine 
dinoflagellate Gambierdiscus toxicus and accumulated in various kinds of reef fish (T. 
Takeshi et at., 2009) 
2 
Hybridomas are hybrid between myeloma cell and mammalian cell that 
producing antibody (B-lymphocytes) (M. Butler, 2004). Myeloma is a tumor or 
cancerous cell that can replicate endlessly while B-lymphocytes are cell that can 
produce a single type of antibody (Prescott et al., 2005). When myeloma cells were 
fused with antibody-producing mammalian spleen cells, it was found that the resulting 
hybrid cells, or hybridomas, produced large amounts of mAb. This product of cell 
fusion combined the desired qualities of the two different types of cells: the ability to 
grow continually, and the ability to produce large amounts of pure antibody.  
 
 
In the bioprocess, there is an upstream and downstream process for production 
of certain biological product like in this study, production of mAb. Upstream process is 
a first step in bioprocess which the biomolecules are grown, usually by bacteria or 
mammalian cell line in bioreactor (fermentation). It involved in cell line development, 
media optimization and cell culture optimization (Feng Li et al., 2005). When it reach 
the desired density, they are harvested and moved to downstream process of the 
bioprocess. In the downstream process, biological product will be purifying to meet 
purity and quality requirement. The downstream section can be divided into three parts: 
a capture section, a purification section and a polishing section (S. Sommerfeld and J. 
Strube, 2005).  
 
 
Process simulators are offering opportunity to shorten or minimize the time and 
cost required for process development. Comparison of process alternatives on a 
consistent basis in simulation gave large number of process ideas to be synthesize and 
analyze interactively in a short time. SuperPro Designer (SPD) developed by Intelligent 
Inc. is software that suitable to simulate the bioprocess operation other than any 
simulation software like Aspen BPS that more towards chemical processes (S. A. Rouf 
et al., 2001). This package has the added advantage that it was specifically developed 
for simulation of biopharmaceutical process unit operations and processes and set up to 
capture the unique unit operational data requirements of biological processes (Ian 
Gosling, 2003).  
3 
1.2 Problem Statement 
 
 
The production cost of mAb in industry is very high, it can achieve around US$ 
100 to 1000 per gram of production cost (S. Sommerfeld and J. Strube, 2005). S.S Farid 
(2007) reported $660 to $1580/ft
2 
and $1756 to $4220/L invested on antibody 
manufacturing site with total site capacities of 2000 L to 20000 L. Instead of that, low 
amount of mAb produced cannot afford the high demand of this rapidly growing 
therapeutics.  
 
 
Because of the high production cost and low amount of product, the selling price 
becoming so high that ranges from US$5000 per gram for mAb to US$ 1 million for 
erythropoietin (S. K. W. Oh et al., 2004). To fulfill the high demand and lowering the 
cost mAb, large scale production of mAb had become one of the top priorities in 
biopharmaceutical industry.  
 
 
Simulation can become one of the tools to minimize cost and time for 
production of mAb. Optimization can be made by firstly doing the simulation before 
undergo the large scale production and eliminate the trial-and-error step in 
biopharmaceutical process.  
 
 
 
 
1.3 Objectives 
 
 
The objective of this research is to study the upstream and downstream process 
of mAb from laboratory data base on SPD simulation. It is also to discover the potential 
for the large scale production of mAb by using the desired SPD. 
 
 
 
 
4 
1.4 Scope of the Study 
 
 
Model for this study is hybridoma used to cultivate antibody towards Congenital 
Adrenal Hyperplasia (CAH), inherent disease that able to cause death within 14 days 
infant and abnormal sex.  Scope in this study is to compare the simulation result with 
laboratory experiment data. The scope is also to build and simulate the large scale 
upstream process for mAb production by using the laboratory data.  Other than that, the 
scope is to propose downstream process by build a several flow design for purification 
of mAb and analyze the best process base on yield and purity.  
 
 
 
 
1.5 Rationale and Significance 
 
 
This study has a potential to minimize cost and time for production of 
monoclonal antibody by doing the simulation first before furthering in clinical or large-
scale production. Traditionally, process development of mammalian cell culture is 
based on trial-and-error experimentation. So, process simulation can overcome the trial-
and error process development and facilitate rapid process improvement without 
extensive experimentation or disrupting existing operations.   
 
 
 
 
 
 
 
  
CHAPTER 2 
 
 
 
 
LITERATURE REVIEW 
 
 
 
 
2.1 Upstream Process 
 
 
In the bioreactor, cells survive, grow, die and produce mAb depending on their 
culture environment. Kinetic equation need to be developed to describe cell growth, 
nutrient consumption and product generation, the concentration of substrates and 
products is a factor for kinetics of hybridoma culture (L. Legazpi et. al., 2005). In cell 
growth, glucose and glutamine are assumed to be the main substrate while ammonia and 
lactate produced from glucose and glutamine metabolism are assumed to be inhibitory 
to cell growth. Glutamine is also assumed as main limiting substrate for antibody 
production (J. D. Jae and J. P. Barford, 2000). 
 
 
 
 
Figure 2.1: Main metabolic routes for hybridoma cells (L. Legazpi et. al., 2005)
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Specific of cell growth rate based on the concentration of key nutrient (glucose 
and glutamine) and the metabolites (lactate and ammonia) that follow monod kinetics. 
Cell death rate is based on the function of ammonia concentration that accumulates in 
the culture. For cell metabolism, concentration of nutrients and metabolites are compute 
by performing mass balance around bioreactor (C. Contoravdi et. al., 2007). 
 
 
Model improvement over pre-existing model were developed by model 
development for batch and fed-batch operations were derived based on initial metabolic 
flux analysis(MFA) and the coefficient or parameters value for model equation were 
estimated by using quadratic programming(QP) and Metropolis-Hastings algorithm. 
Integrated model (combination between metabolites and biomass model) is capable of 
predicting concentration for substrates, extracellular metabolites, and viable and dead 
cell concentration (P. Dorka et al., 2009). 
 
 
Many kinetic expressions and a large number of parameters are involved 
resulting in a complex identification problem. It is not possible to estimate 
simultaneously all parameters with the mathematical analysis, so strategy to narrow 
down the parameters involve should be taken by: firstly, estimate all parameters that 
could be analyzed independently, then the most insensitive parameters (mainly half-
saturation constants-taken from literature), most sensitive parameters estimate by non-
linear regression analysis, and finally improve model by tuning manually the most 
insensitive parameters (A. Teixeira et al., 2005). 
 
 
 From the study of A. C. Baughman et al. (2009) by taking the Gao et al. (2007) 
as case study, they state that half of generic metabolic reconstruction did not function 
significantly during major phase of the culture and that make the 32 reaction is reduced 
to 16 reactions. These 16 reactions then is further compacted by some technique which 
combine reactions that share common metabolites and reducing the reconstruction 
resulted in nine macro reaction. 
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Figure 2.2: Reduced metabolic construction of hybridoma (A. C. Baughman et al., 
2009). 
 
 
Table 2.1: The nine proposed macro-reactions (A. C. Baughman et al., 2009). 
 
  Reaction 1 :     GLC             2LAC 
  Reaction 2 :    GLC + 2GLU            2ALA + 2LAC 
  Reaction 3 :     GLC + 2GLU                2ASP + 2LAC 
  Reaction 4 :     GLU             PRO 
  Reaction 5 :     ASN          ASP + NH3 
  Reaction 6 :     GLN + ASP            ASN + GLU 
  Reaction 7 :   0.0508GLC + 0.0577GLN + 0.006ASN + 0.0201ASP + 
0.0016GLU + 0.0133ALA + 0.0081PRO             BM 
  Reaction 8 :   0.0104GLN + 0.0072ASN + 0.0082ASP + 0.0107GLU + 
0.011ALA + 0.0148PRO             mAb 
  Reaction 9 :  GLN             GLU + NH3 
 
 
 Balance for mammalian cell growth can be describes as an “equation” by 
considering the major “input” and “output” for the biomass formation. The composition 
of cells can be written as a “molecular formula” and an example for the equation for 
hybridoma growth is as Equation 2.1 (S. H. Wei, 2004). 
8 
C6H12C6 (glucose) + 0.15C6.14H12.36N1.50O2.08 (weighted average of amino acids) + 
0.34C5H10N2O2 (glutamine) + 1.39O2       2.37CH1.97N0.26O0.49 (cell mass) + 
0.0058CH1.83N0.14O2.06 (antibody) + 1.54CO2 + 1.28H2O + 1.44C3H6O3 (lactate) + 
0.16NH3 (ammonia) + 0.13 C4H7NO2 (alanine) 
 
Equation 2.1: Stoichiometric equation for Hybridoma (S. H. Wei, 2004). 
 
 
 Y.H. Guan and R.B. Kemp (1999) had developed a stoichiometric equation for 
hybridoma growth reaction to represent the metabolic activity. In their study, it was 
shown that the set of stoichiometric coefficients constitute a validated growth equation 
has a one-to-one corresponding relationship to the metabolic activity of the average cell 
population.for both theoretically and experimentally. Table 2.2 is one of the growth 
reactions for discrete times under activated and triggered condition. 
 
 
Table 2.2: Stoichiometric equation of hybridoma for discrete times under activated and  
triggered condition (Y.H. Guan and R.B. Kemp, 1999). 
 
Metabolic 
condition 
 Metabolic reaction 
Activated 
cells 
Catabolism C6H12O6 + 0.347C5H10N2O3 + 1.7960O2                            
          1.921C3H6O3 + 1.969CO2 + 0.693NH3 + 
0.929H2O 
 Anabolism 0.078C6H12O6 + 0.210C5H10N2O3 + 0.149CO2                            
          1.667CH1.821O0.837N0.252 
 Metabolism C6H12O6 + 0.517C5H10N2O3 + 1.666O2 + 
0.149CO2             
          1.782C3H6O3 + 1.827CO2 + 0.693NH3 + 
0.862H2O + 1.546CH1.821O0.837N0.252 
Triggered 
cells 
Catabolism C6H12O6 + 0.317C5H10N2O3 + 3.836O2                            
          1.196C3H6O3 + 3.994CO2 + 0.633NH3 + 
3.044H2O 
 Anabolism 0.184C6H12O6 + 0.092C5H10N2O3 + 0.054CO2                            
          1.614CH1.938O0.922N0.114 
 Metabolism C6H12O6 + 0.345C5H10N2O3 + 3.240O2          
1.010C3H6O3 + 3.327CO2 + 0.535NH3 + 
2.571H2O + 1.363CH1.938O0.922N0.114  
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Commercial success of mAb had led to the need for large scale production in 
mammalian cell culture. Rapid expansion had increase the bioreactor size and 
optimization effort are improved since then for cell expression and process optimization 
like fed-batch cultures (J. R. Birch and A. J. Racher, 2006). K. H. Ting and K. A. 
McDonald (2009) had stated that bioreactor designs must provide an environment that 
is able to optimize the growth and productivity of the genetically engineered host cells 
and design of effective bioreactor should consider growth, nutrient uptake and 
production kinetics, oxygen and heat transfer, and fluid hydrodynamics.  
 
 
Stirred tank bioreactor have been widely used for commercially antibody 
production by using cell lines like CHO, hybridoma and NSO and the agitation rates in 
these reactors are generally kept between 10 to 40 rpm depending upon the sensitivity 
of the cell lines being cultured (E. Jain and A. Kumar, 2008). L. Legazpi et al. (2005) 
had conducted a study of agitation effect to the hybridoma cell by using rocker set-up 
and shown high value of specific death rate provoked decreasing in number of viable 
cell.  
 
 
Agitation and aeration are critical consideration in bioreactor for mammalian 
cell because it caused physical cell damage by induced hydrodynamic shear by agitation 
and bubble damage caused by mass transfer gas sparging (D. M. Marks, 2003). 
 
 
 
10 
 
2.2 Downstream Process 
 
 
 After the upstream section or the fermentation process, the production of mAb is 
further proceed to downstream section to be purified according to the product quality 
requirement and there are typical substances that need to be separated in downstream 
section. Cell culture medium like amino acid, inorganic salts and medium supplement 
like bovine serum and proteins need to be separated in downstream process. Other than 
that, substances like intact cells, cell debris, host cell protein and DNA are also 
separated in order to have pure desired product (S. Sommerfeld and J. Strube, 2005).  
 
 
 
 
Figure 2.3: Downstream processing task (S. Sommerfeld and J. Strube, 2005). 
 
 
As known today, mAb is used in many applications such as diagnosis and 
treatment of certain diseases like cancer therapy. Therapeutic treatment for cancer by 
using mAb produced by murine hybridomas cultured in a cell bioreactor in serum free 
conditions were harvested from supernatants and further purified by downstream 
process (A. L. Horenstein et al., 2003).  
11 
 
 
 
Figure 2.4: Major stages of the downstream processing of mAb for cancer therapy (A. 
L. Horenstein et al., 2003). 
 
 
Limits imposed by the technology, equipment and facilities that are available 
had made downstream processes to take proportional response to the limits.  As a result, 
manufacturers are intent to explore several ways or strategies of streamlining product 
recovery and purification like decreasing the number of steps, avoiding complex steps 
and reducing raw materials costs. In addition, alternative formats for recovery and 
purification unit operations are being reconsidered include expanded and simulated 
moving beds, membrane chromatography and non-chromatographic methods such as 
flocculation, precipitation, crystallization and aqueous two-phase systems (D. Low et 
al., 2006). 
 
 
A. A. Shukla et al. (2006) had described a flexible, generic platform for mAb 
downstream processing that they develop at Amgen and applied for the production of 
over 20 molecules over a range of scales ranging from clinical production to 
commercial launch.  
12 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Generic Downstream process for mAb (A. A. Shukla et al., 2006) 
 
Cell culture harvest 
- Aim to reduce host cell protein  
  impurities, high molecular weight  
  aggregates, DNA, etc after Protein   
  A chromatography step.  
- ex: cation-exchange   
  chromatography(CEX), anion- 
  exchange chromatography(AEX), 
 
Viral filtration 
Ultrafiltration/diafiltration(UF/DF) 
Protein A Chromatography 
Viral inactivation 
Chromatographic polishing step (2) 
- Viral reduction on    
   chromatographic steps to assure  
   safety of product by elution at low   
   pH. 
- Serves as capture step to reduce  
   volume and has proved to be very  
   selective for mAb. 
- can achieved mAb yield > 99%  
   purity. 
 
- Centrifugation by using  
  continuous disk-stack centrifuge   
  to remove cell and cell debris. 
- followed by depth filtration step(s)  
  to remove residual cellular debris. 
-Completion of downstream  
  process, product is buffer  
  exchanged into the formulation 
buffer. 
- Employed in the platform process  
  complement the low pH viral   
  inactivation step. 
- placed in the platform process  
  following either one of the  
  polishing chromatographic step. 
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2.2.1 RIPP Scheme 
 
 
In a broader term, bioseparations engineering refers to the systematic study of 
the scientific and engineering principles utilized for the large scale purification of 
biological products. Bioseparation processes are based on multiple techniques and RIPP 
scheme is commonly used in bioseparation. RIPP stand for Recovery, Isolation, 
Purification and Polishing that involves use of low resolution techniques first for 
recovery and isolation followed by high resolution techniques for purification and 
polishing (R. Ghosh, 2006). 
 
 
Table 2.3: RIPP scheme for downstream process (R. Ghosh, 2006). 
 
Stage Objectives Typical unit operations 
Recovery  
(separation of insoluble) 
- Remove or collect cells,    
   cell debris 
- Reduce volume 
Filtration, sedimentation, 
extraction, adsorption, 
centrifugation 
Isolation - Remove materials having   
   properties widely  
   different from those target  
   product 
- Reduce volume 
Extraction, adsorption, 
ultrafiltration, 
precipitation 
Purification - Remove remaining   
   impurities, which  
   typically are similar to  
   those or target product 
Chromatography, affinity 
methods, precipitation 
Polishing - Remove liquids 
- Convert product to  
  crystalline form (not  
  always possible) 
Drying, crystallization  
 
 
The objective of RIPP scheme is mainly to reduce volume from the fermentation 
process until get the pure biological product. The first step that is the recovery step is to 
remove or collect the cells and cell debris by some unit operations like filtration, 
sedimentation and centrifugation. Second step that is the isolation step is to remove the
14 
 
materials that having widely different properties form the target product. This can be 
done by using extraction, adsorption, precipitation and ultrafiltration.  
 
 
The next step is purification step that remove remaining impurities that had 
typical similar type of the target product. This step is very important for downstream 
process and can be done by using chromatography, affinity and precipitation. The final 
step is polishing where it is not always possible in downstream process. The objective 
of this step is to remove liquid and convert the target product into crystalline form by 
drying and crystallization process.   
 
 
 
 
2.2.2 Centrifugation  
 
 
 Centrifuge is a device that separates particles from suspensions or even 
macromolecules from solutions according to the size, shape and density by subjecting 
these dispersed system to artificially induced gravitational fields. After the separation 
complete, the suspension cells will separate to supernatant and precipitate according to 
the density of substance in the centrifugation. A disc stack centrifuge is a special type of 
preparative centrifuge which is compact in design and gives better solid-liquid 
separation than the standard tubular bowl centrifuge (R. Ghosh, 2006).  
 
 
For mAb production, centrifugation is the first unit operation that acts as cell 
removal at the capture step of mAb purification before further process in downstream 
section (S. Sommerfeld and J. Strube, 2005).  
 
 
 
 
